Literature DB >> 23275270

Patterns of failure in colorectal patients with liver metastases after yttrium-90 radioembolization.

Caitlin A Schonewolf1, Bhavik Patel, Rebekah H Gensure, Venkat Narra, Bruce G Haffty, John L Nosher, Salma K Jabbour.   

Abstract

OBJECTIVES: To assess patterns of failure and factors affecting recurrence patterns in colorectal cancer patients treated with Y-labeled resin microspheres for metastatic liver disease.
METHODS: We retrospectively reviewed 30 colorectal patients treated with Yttrium-90 radioembolization and assessed follow-up computed tomography scans and positron emission tomography scans to determine disease outcomes. All patients were included in survival analysis. Twenty-six patients with hepatic metastases were assessed for patterns of failure after radioembolization treatment and grouped into 3 patterns: (1) hepatic; (2) extrahepatic; and (3) intrahepatic and extrahepatic.
RESULTS: The median overall survival and progression-free survival for all colorectal patients treated with radioembolization was 9.4 and 3.2 months, respectively. Overall survival and progression-free survival were not significantly different between patterns of failure (P=0.43 and 0.26, respectively). Logistic regression analysis demonstrated a trend toward the predictive value of tumor volume in determining patterns of failure. Smaller tumor volumes had a higher predictive probability for extrahepatic failure than larger tumor volumes (P=0.057). Tumor volumes <300 mL were predictive for extrahepatic failure patterns compared with hepatic recurrence (P=0.046).
CONCLUSIONS: Radioembolization with Y-labeled resin microspheres continues to be an effective salvage treatment for colorectal liver metastases. Analysis of patterns of radiologic failure demonstrated that patients treated by radioembolization develop a greater proportion of extrahepatic failure. Tumor volumes >300 mL were predictive for hepatic recurrence, suggesting that increased dosing or retreatment of these lesions may lead to improved hepatic control of disease and better patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23275270     DOI: 10.1097/COC.0b013e318277d610

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

1.  Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.

Authors:  Darren R Carpizo; Rebekah H Gensure; Xin Yu; Vyacheslav M Gendel; Samuel J Greene; Dirk F Moore; Salma K Jabbour; John L Nosher
Journal:  J Vasc Interv Radiol       Date:  2013-12-20       Impact factor: 3.464

2.  Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases.

Authors:  Ieva Kurilova; Regina G H Beets-Tan; Jessica Flynn; Mithat Gönen; Gary Ulaner; Elena N Petre; F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Elisabeth G Klompenhouwer; Andrea Cercek; Nancy A Kemeny; Constantinos T Sofocleous
Journal:  Clin Colorectal Cancer       Date:  2018-09-13       Impact factor: 4.481

Review 3.  The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review.

Authors:  Salvatore Annunziata; Giorgio Treglia; Carmelo Caldarella; Federica Galiandro
Journal:  ScientificWorldJournal       Date:  2014-02-02

Review 4.  Predictors and prognosticators for survival with Yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastasis.

Authors:  Meaghan S Dendy; Johannes M Ludwig; Hyun S Kim
Journal:  Oncotarget       Date:  2017-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.